Shares of Eli Lilly (LLY) jumped Wednesday after the U.S. government gave the green light for the company's blockbuster GLP-1 drug to be used as an obesity treatment. In a widely expected move, the U.S. Food and Drug Administration on Wednesday approved Eli Lilly's GLP-1 drug for weight loss. Eli Lilly said it will market the drug as an obesity treatment under the name Zepbound. Shares of Eli Lilly — which have climbed more than 67% year-to-date — soared nearly 2% Wednesday afternoon, to $611.36 apiece. Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

---

Persons: Eli Lilly, LLY, Eli Lilly's GLP, Eli Lilly —, Eli Lilly's, Jim Cramer, Jim, Jim Cramer's, Cristina Arias Organizations: U.S, U.S . Food, Drug Administration, American Heart Association, Novo Nordisk, Novo, GLP, Nordisk's GLP, FDA, Nordisk, CNBC, Company, Pharmaceutical Locations: U.S, Danish, Alcobendas, Madrid, Spain